SEARCH

SEARCH BY CITATION

References

  • 1
    Dissanayake AS & Truelove SC. A controlled therapeutic trial of sulphasalazine. Gut 1973; 14: 93 6.
  • 2
    Das KM, Eastwood MA, Mc Manus JPA, Sircus W. Adverse reaction during salicylazosulphapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1973; 289: 491 5.
  • 3
    Campieri M & Gionchetti P. The use of salicylates in patients with inflammatory bowel disease. Clinical Challenges in Inflammatory Bowel Disease, Diagnosis Prognosis and Treatment. Falk Symposium. Lancaster, UK: Kluwer Academic Publishers, 1997: 141 5.
  • 4
    Sutherland LR, May GR, Shaffer EA. Sulphasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern: Med 1993; 118: 540 9.
  • 5
    Sartor RB. Pathogenesis and immune mechanisms of chronic inflammatory bowel Disease. Am J Gastroenterol 1997; 2: 5S 11S.
  • 6
    Fuller R. Probiotics in human medicine. Gut 1991; 32: 439 42.
  • 7
    Mao Y, Nobaek S, Kasravi B, et al. The effects of Lactobacillus strains and oat fibre on methotrexate-induced Enterocolitis in rats. Gastroenterology 1996; 111: 334 44.
  • 8
    Fabia R, Ar’Rajab A, Johansson ML, et al. Impairment of bacterial flora in human ulcerative colitis and experimental colitis in the rat. Digestion 1993; 54: 248 55.
  • 9
    Madsen KL, Tavrini MM, Doyle JSG, et al. Lactobacillus sp prevents developments of enterocolitis in interleukin-10 gene deficient mice. Gastroenterology 1997; 112: A 1030A 1030 (Abstract).
  • 10
    Schultz M, Veltkamp C, Dielman LA, Wyrick PB, Tonkonogy SL, Sartor RB. Continuous feeding of lactobacillus plantarum attenuates estabilished colitis in interleukin-10 deficient mice Gastroenterology 1988; 114: 44; G4426G4426 (Abstract).
  • 11
    Kruis W, Schuts E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia Coli preparation and Mesalazina in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997; 11: 853 8.
  • 12
    Rembacken BJ, Snelling AM, Hawkey PM, Dixon ATR. A double blind trial of non pathogenic IX. coli vs mesalazine for the treatment of ulcerative colits. Gut 1997; 41(Suppl. 3): 39113911.
  • 13
    Baron JH, Connel AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J 1964; 1: 89 92.
  • 14
    Truelove SC & Richard WCD. Biopsy studies in ulcerative colitis Br Med J 1956; 1: 1315 8.
  • 15
    Summanen P & Baron EJ, et al., eds. Wadsworth Anaerobic Bacteriology Manual, Fifth Edition. Singapore: STAR Publishers Co, 1993.
  • 16
    Biavati B, Sgorbati B, Scardovi V. The genus Bifidobacterium. In: Balows A, Tripes HG, Dworkin M, Harder W, Schleifer KH, eds. The Prokariotes Handbook on the Biology of the Bacteria. Berlin: Springer-Verlag, 1992: 816–33.
  • 17
    Bengmark S. Ecological control of the gastrointestinal tract. The role of probiotic flora. Gut 1998; 42: 2 7.
  • 18
    Fernandes CF, Shahami KM, Amer MA. Therapeutic role of dietary lactobacilli and lactobacilli fermented dairy products. FEMS Microbiolol Rev 1987; 46: 343 56.
  • 19
    Salminen S, Deighton M, Gorbach S. Lactic acid bacteria in health and disease In:von : Salminen S, Wright A, eds. Lactic Acid Bacteria. New York: Dekker, 1993: 199–225.
  • 20
    Ahn C & Stiles ME. Antibacterial activity of lactic acid bacteria isolated from vacuum-packed meats. J Appl Bacteriol 1990; 69: 302 10.
  • 21
    Malin M, Suomalainen H, Saxelin M, Isolauri E. Promotion of IgA immune response in patients with Crohn’s disease by oral Bacteriotherapy with Lactobacillus GG. Ann Nutr Metab 1996; 40: 137 45.
  • 22
    Axelsson LT, Chung TC, Dobrogosz WJ, Lindgreen SE. Production of a broad spectrum antimicrobial substance by Lactobacillus reuteri. Microb Ecol Health Dis 1989; 2: 131 6.
  • 23
    Gorbach SL. Lactic acid bacteria and human health. Ann Med 1990; 22: 37 41.
  • 24
    McDonought FE, Wells P, Wong NP, Hitchins AD, Bodwell CE. Role of vitamins and mineral in growth stimulation of rats fed yogurt. Fed Proc 1983; 42: 556556.
  • 25
    Gionchetti P, Rizzello F, Venturi A, et al. Maintenance treatment of chronic pouchitis: a randomised placebo-controlled trial with a new probiotic preparation. Gastroenterology 1988; 114: 44; G4037G4037.
  • 26
    Lee YK & Salminen S. The coming of age of probiotics. Trends Food Sci Technol 1995; 6: 241 5.
  • 27
    Bengmark S. Econutrition and health maintenance – a new concept to prevent GI inflammation ulceration and sepsis. Clin Nutrition 1996; 15: 1 10.
  • 28
    Berg RD. Probiotic, prebiotic or ‘combiotics’? Trends Microbiol 1998; 6: 89 92.